Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

Three years af­ter clos­ing out its first €660 mil­lion ($730.5 mil­lion) pri­vate eq­ui­ty fund, Lon­don-based GHO Cap­i­tal Part­ners has sealed a mam­moth $1 bil­lion-plus sec­ond fund, a feat it has claimed is the biggest-ever fo­cused on Eu­ro­pean health­care.

The in­vest­ment firm has al­ready in­ject­ed cap­i­tal in­to ac­tive phar­ma­ceu­ti­cal in­gre­di­ent man­u­fac­tur­er Ster­ling Phar­ma So­lu­tions and bio­an­a­lyt­i­cal test­ing com­pa­ny BioAg­i­lytix in the first quar­ter of 2019. GHO’s Fund II will in­vest in the out­sourced ser­vices, phar­ma and medtech sec­tors, the com­pa­ny said on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER